Fluorouracil and dose-dense adjuvant chemotherapy in patients with early-stage breast cancer (GIM2): end-of-study results from a randomised, phase 3 trialLucia Del Mastro, A Parisi, G Canavese et al.|The Lancet Oncology|2022Cited by 50
Human epidermal growth factor receptor 2 dual blockade with trastuzumab and pertuzumab in real life: Italian clinical practice versus the CLEOPATRA trial resultsSabino De Placido, Grazia Arpino, Mario Giuliano et al.|The Breast|2018Cited by 35
PONDx: real-life utilization and decision impact of the 21-gene assay on clinical practice in ItalyFrancesco Cognetti, Sandro Barni, Riccardo Masetti et al.|npj Breast Cancer|2021Cited by 29
T-DM1 versus pertuzumab, trastuzumab and a taxane as first-line therapy of early-relapsed HER2-positive metastatic breast cancer: an Italian multicenter observational studyFrancesco Schettini, Lucia Del Mastro, Benedetta Conte et al.|ESMO Open|2021Cited by 22
Tailoring neoadjuvant treatment of HR-positive/HER2-negative breast cancers: Which role for gene expression assays?Giovanna Garufi, Fabio Puglisi, Luisa Carbognin et al.|Cancer Treatment Reviews|2022Cited by 20